Payment overview · 2025
General Payments
$4,423.31
166 reported records · 33 companies
Healthcare provider profile · identity verified
Saima Khurram, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CANTON, GA · NPI 1710149455
Verified facts
What the public records show
CMS Open Payments records show Saima Khurram, MD received $4,423.31 in general payments during 2025 across 166 reported records.
UCB, Inc. accounted for 9.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Fycompa, Nurtec Odt, Panzyga, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rytary by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fycompa by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Octapharma USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 1567 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Panzyga by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Panzyga by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gammagard Liquid by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $397.25 | 9.0% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $392.60 | 8.9% | 17 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $373.90 | 8.4% | 9 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $341.59 | 7.7% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $317.62 | 7.2% | 15 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $269.41 | 6.1% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $269.19 | 6.1% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $227.71 | 5.2% | 6 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $198.52 | 4.5% | 11 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $186.12 | 4.2% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $152.86 | 3.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $134.56 | 3.0% | 6 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $114.05 | 2.6% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $106.30 | 2.4% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$105.51 | 2.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $99.77 | 2.3% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $92.24 | 2.1% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.80 | 1.9% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $81.22 | 1.8% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $52.67 | 1.2% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$51.74 | 1.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $50.78 | 1.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.50 | 1.1% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $41.21 | 0.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $38.64 | 0.9% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $27.43 | 0.6% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $26.60 | 0.6% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $26.13 | 0.6% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $25.33 | 0.6% | 1 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $24.03 | 0.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $21.78 | 0.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.64 | 0.5% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $21.61 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,311.61 | 164 |
| Education | $111.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $318.87 | 9 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $317.62 | 15 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $269.41 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $233.74 | 10 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $227.71 | 6 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $198.52 | 11 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $197.01 | 8 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $186.12 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $170.22 | 7 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $159.75 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $152.86 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $136.04 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $136.04 | 6 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $134.56 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $134.56 | 6 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $133.15 | 5 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $127.38 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $124.19 | 6 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $118.28 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $114.05 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $92.24 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $91.10 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $82.80 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $76.48 | 3 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $61.36 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $51.74 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $51.46 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $50.78 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $50.50 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $34.63 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $29.44 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $28.97 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $27.43 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Vyrsa V1 Normalized: vyrsa v1 |
Device | Globus Medical, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 101 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 60 | exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
101 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Octapharma USA, Inc. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 1567 supporting records · 974 recipient NPIs · example record 1245074635 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 493 | 155 |
| Gabapentin | Gabapentin | 443 | 131 |
| Pregabalin | Pregabalin | 350 | 103 |
| Donepezil Hcl | Donepezil Hcl | 342 | 120 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 325 | 98 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 60 |
| Trazodone Hcl | Trazodone Hcl | 225 | 60 |
| Levetiracetam | Levetiracetam | 169 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 39 |
| Divalproex Sodium | Divalproex Sodium | 144 | 36 |
| Clonazepam | Clonazepam | 122 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 109 | 34 |
| Sertraline Hcl | Sertraline Hcl | 105 | 28 |
| Botox | Onabotulinumtoxina | 101 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 27 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 80 | 19 |
| Topiramate | Topiramate | 77 | 24 |
| Buspirone Hcl | Buspirone Hcl | 73 | 16 |
| Rytary | Carbidopa/Levodopa | 73 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 37 |
| Sumatriptan Succinate | Sumatriptan Succinate | 71 | 26 |
| Lamotrigine | Lamotrigine | 68 | 17 |
| Alprazolam | Alprazolam | 66 | 27 |
| Aimovig Autoinjector | Erenumab-Aooe | 62 | 13 |
| Baclofen | Baclofen | 62 | 15 |
| Mirtazapine | Mirtazapine | 60 | 17 |
| Nurtec Odt | Rimegepant Sulfate | 60 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 16 |
| Primidone | Primidone | 56 | 19 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 54 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 52 | 22 |
| Methotrexate | Methotrexate Sodium | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | 12 |
| Tramadol Hcl | Tramadol Hcl | 44 | 25 |
| Lacosamide | Lacosamide | 43 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 39 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 36 |
| Divalproex Sodium Er | Divalproex Sodium | 35 | suppressed |
| Prednisone | Prednisone | 34 | 17 |
| Ubrelvy | Ubrogepant | 34 | suppressed |
| Briviact | Brivaracetam | 32 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 20 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | 11 |
| Aptiom | Eslicarbazepine Acetate | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | 12 |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,423.31 · 166 records | UCB, Inc. | AMYVID, AUSTEDO XR, AVONEX, Albuked, BOTOX, Briviact, CREXONT, EPIDIOLEX, Exablate, FIRDAPSE, FYCOMPA, Fintepla, GAMMAKED, HYQVIA, Hizentra, INBRIJA, INGREZZA, KEDRAB, KESIMPTA, KISUNLA, KOATE, LEQEMBI, NOURIANZ, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, QULIPTA, Qelbree, REXULTI, RhoGAM Ultra-Filtered PLUS, Rystiggo, Senza, Symbravo, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, Vyrsa V1, Xeomin, ZAVZPRET, Zilbrysq | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error